Symbols / CBIO Stock $19.97 -5.93% Crescent Biopharma, Inc.

Healthcare • Biotechnology • United States • NCM
CBIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Joshua T. Brumm
Exch · Country NCM · United States
Market Cap 550.67M
Enterprise Value 479.96M
Income -162.08M
Sales 11.88M
FCF (ttm) —
Book/sh 5.41
Cash/sh 5.69
Employees 44
Insider 10d —
IPO Jan 10, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.78
PEG —
P/S 46.34
P/B 3.69
P/C —
EV/EBITDA —
EV/Sales 40.39
Quick Ratio 13.33
Current Ratio 13.78
Debt/Eq 0.84
LT Debt/Eq —
EPS (ttm) -5.88
EPS next Y -2.94
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-29
Earnings (prior) 2026-04-29
ROA —
ROE —
ROIC —
Gross Margin 100.00%
Oper. Margin -23.80%
Profit Margin 0.00%
Shs Outstand 27.57M
Shs Float 14.60M
Insider Own 5.81%
Instit Own 96.08%
Short Float 19.84%
Short Ratio 9.00
Short Interest 2.40M
52W High 28.00
vs 52W High -28.68%
52W Low 8.72
vs 52W Low 129.01%
Beta —
Impl. Vol. —
Rel Volume 1.05
Avg Volume 248.87K
Volume 260.49K
Target (mean) $29.43
Tgt Median $30.00
Tgt Low $22.00
Tgt High $35.00
# Analysts 7
Recom Strong_buy
Prev Close $21.23
Price $19.97
Change -5.93%
About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.43
Mean price target
2. Current target
$19.97
Latest analyst target
3. DCF / Fair value
$29.43
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$19.97
Low
$22.00
High
$35.00
Mean
$29.43

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-02 main HC Wainwright & Co. Buy → Buy $22
2026-01-21 init Guggenheim — → Buy $35
2025-08-27 reit HC Wainwright & Co. Buy → Buy $25
2025-08-25 init Jefferies — → Buy $26
2025-08-11 init HC Wainwright & Co. — → Buy $25
2025-07-14 init Wedbush — → Outperform $27
2025-06-25 init Stifel — → Buy $28
News
RSS: Latest CBIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-15 BRUMM JOSHUA T. Chief Executive Officer — 55,117 $0.00 $0
2025-12-15 LYNCH RYAN Officer and Treasurer — 12,378 $0.00 $0
2025-12-15 SCALZO RICHARD WILLIAM Chief Financial Officer — 19,422 $0.00 $0
2025-12-15 MCNEILL JONATHAN President — 25,507 $0.00 $0
2025-12-15 DOUGHTY CHRISTOPHER GRANT Officer — 22,714 $0.00 $0
2025-12-15 IM ELLIE EUNKYUNG Officer — 21,298 $0.00 $0
2025-12-15 BISPHAM BARBARA HARLIN General Counsel — 18,422 $0.00 $0
2025-12-15 PINKAS JAN Officer — 22,507 $0.00 $0
2025-12-04 FAIRMOUNT FUNDS MANAGEMENT LLC Director and Beneficial Owner of more than 10% of a Class of Security — 1,360,000 $13.41 $18,237,600
2024-07-30 INVUS PUBLIC EQUITIES ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 1,379,119 $0.22 $315,262
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31
Total Revenue
10.84
Operating Revenue
10.84
Operating Expense
163.48
Research And Development
138.09
Selling General And Administration
25.39
General And Administrative Expense
25.39
Salaries And Wages
14.56
Other Gand A
10.83
Total Expenses
163.48
Operating Income
-152.63
Total Operating Income As Reported
-152.63
EBITDA
-149.67
Normalized EBITDA
-149.67
Reconciled Depreciation
0.08
EBIT
-149.76
Net Income
-153.94
Pretax Income
-151.94
Net Non Operating Interest Income Expense
0.69
Interest Expense Non Operating
2.19
Net Interest Income
0.69
Interest Expense
2.19
Interest Income Non Operating
2.88
Interest Income
2.88
Tax Provision
2.00
Tax Rate For Calcs
0.00
Tax Effect Of Unusual Items
0.00
Net Income Including Noncontrolling Interests
-153.94
Net Income From Continuing Operation Net Minority Interest
-153.94
Net Income From Continuing And Discontinued Operation
-153.94
Net Income Continuous Operations
-153.94
Normalized Income
-153.94
Net Income Common Stockholders
-153.94
Diluted EPS
-12.81
Basic EPS
-12.81
Basic Average Shares
10.41
Diluted Average Shares
10.41
Diluted NI Availto Com Stockholders
-153.94
Line Item Trend 2025-12-31 2024-12-31
Total Assets
240.29
+574.66%
35.62
Current Assets
236.66
+579.96%
34.80
Cash Cash Equivalents And Short Term Investments
213.19
+513.22%
34.77
Cash And Cash Equivalents
213.19
+513.22%
34.77
Cash Financial
213.19
+513.22%
34.77
Receivables
18.00
0.00
Accounts Receivable
18.00
0.00
Prepaid Assets
4.18
0.00
Other Current Assets
1.28
+3263.16%
0.04
Total Non Current Assets
3.64
+347.48%
0.81
Net PPE
2.31
0.00
Gross PPE
2.31
0.00
Other Properties
2.31
—
Non Current Deferred Assets
—
0.81
Other Non Current Assets
1.32
+62.73%
0.81
Total Liabilities Net Minority Interest
37.28
-27.04%
51.10
Current Liabilities
36.07
+275.20%
9.61
Payables And Accrued Expenses
21.36
+123.95%
9.54
Payables
18.14
+147.50%
7.33
Accounts Payable
10.00
+9242.99%
0.11
Current Accrued Expenses
3.22
+45.84%
2.21
Pensionand Other Post Retirement Benefit Plans Current
5.12
+34040.00%
0.01
Total Tax Payable
8.00
0.00
Current Debt And Capital Lease Obligation
0.43
—
Current Capital Lease Obligation
0.43
0.00
Current Deferred Liabilities
4.16
0.00
Current Deferred Revenue
4.16
0.00
Other Current Liabilities
5.00
+8096.72%
0.06
Total Non Current Liabilities Net Minority Interest
1.21
-97.09%
41.48
Long Term Debt And Capital Lease Obligation
1.21
-96.77%
37.48
Long Term Debt
—
37.48
Long Term Capital Lease Obligation
1.21
0.00
Preferred Securities Outside Stock Equity
0.00
-100.00%
4.00
Stockholders Equity
203.01
+1411.53%
-15.48
Common Stock Equity
199.01
+1385.69%
-15.48
Capital Stock
4.03
+402700.00%
0.00
Common Stock
0.03
+2700.00%
0.00
Preferred Stock
4.00
0.00
Share Issued
30.45
+56.14%
19.50
Ordinary Shares Number
30.45
+56.14%
19.50
Additional Paid In Capital
370.79
+15433.85%
2.39
Retained Earnings
-171.81
-861.60%
-17.87
Total Equity Gross Minority Interest
203.01
+1411.53%
-15.48
Total Capitalization
203.01
+822.66%
22.00
Working Capital
200.58
+696.28%
25.19
Invested Capital
199.01
+804.48%
22.00
Total Debt
1.64
-95.61%
37.48
Net Debt
—
2.72
Capital Lease Obligations
1.64
0.00
Net Tangible Assets
203.01
+1411.53%
-15.48
Tangible Book Value
199.01
+1385.69%
-15.48
Dueto Related Parties Current
0.14
-98.06%
7.22
Interest Payable
0.00
-100.00%
0.85
Preferred Stock Equity
4.00
—
Line Item Trend 2025-12-31
Operating Cash Flow
-71.53
Cash Flow From Continuing Operating Activities
-71.53
Net Income From Continuing Operations
-153.94
Depreciation Amortization Depletion
0.08
Depreciation
0.08
Depreciation And Amortization
0.08
Other Non Cash Items
82.40
Stock Based Compensation
13.30
Change In Working Capital
-13.37
Change In Receivables
-18.00
Changes In Account Receivables
-18.00
Change In Prepaid Assets
-5.01
Change In Payables And Accrued Expense
0.36
Change In Accrued Expense
5.36
Change In Payable
-5.00
Change In Account Payable
2.08
Change In Other Working Capital
4.32
Change In Other Current Liabilities
4.96
Investing Cash Flow
-72.92
Cash Flow From Continuing Investing Activities
-72.92
Net PPE Purchase And Sale
-0.92
Purchase Of PPE
-0.92
Capital Expenditure
-72.92
Net Intangibles Purchase And Sale
-72.00
Purchase Of Intangibles
-72.00
Financing Cash Flow
322.98
Cash Flow From Continuing Financing Activities
322.98
Net Issuance Payments Of Debt
0.00
Issuance Of Debt
0.00
Long Term Debt Issuance
0.00
Net Long Term Debt Issuance
0.00
Net Common Stock Issuance
321.71
Common Stock Payments
-0.18
Repurchase Of Capital Stock
-0.18
Proceeds From Stock Option Exercised
0.01
Net Other Financing Charges
1.27
Changes In Cash
178.53
Beginning Cash Position
34.77
End Cash Position
213.30
Free Cash Flow
-144.45
Common Stock Issuance
321.89
Issuance Of Capital Stock
321.89
Net Preferred Stock Issuance
0.00
Preferred Stock Issuance
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category